Additionally, in the work of Jiang et al. (2021) [7], the therapeutic dosing of recombinant ISM1 improved glucose tolerance to the same degree as metformin, enhanced diabetes in diet-induced obese mice, and ameliorated hepatic steatosis in a diet-induced fatty liver mouse model, establishing that recombinant ISM1 and its derivatives may be explored for therapeutic purposes and may offer certain advantages over current monotherapies. The gene discussed is ISM1; the disease is Hepatic steatosis.